Sonoma Pharmaceuticals, Inc. (SNOA)
USD 2.27
(9.13%)
USD 2.27
(9.13%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 9.44 Million USD | 4.41% |
| 2023 | 9.04 Million USD | -8.43% |
| 2022 | 9.88 Million USD | -1.28% |
| 2021 | 10 Million USD | -33.3% |
| 2020 | 15 Million USD | -25.49% |
| 2019 | 20.13 Million USD | -6.33% |
| 2018 | 21.49 Million USD | 15.33% |
| 2017 | 18.64 Million USD | 7.37% |
| 2016 | 17.36 Million USD | 24.49% |
| 2015 | 13.94 Million USD | -3.47% |
| 2014 | 14.44 Million USD | 2.34% |
| 2013 | 14.11 Million USD | -7.01% |
| 2012 | 15.18 Million USD | 11.25% |
| 2011 | 13.64 Million USD | 14.73% |
| 2010 | 11.89 Million USD | -40.85% |
| 2009 | 20.1 Million USD | -14.46% |
| 2008 | 23.5 Million USD | 11.8% |
| 2007 | 21.02 Million USD | 13.46% |
| 2006 | 18.53 Million USD | 31.01% |
| 2005 | 14.14 Million USD | 0.0% |
| 2004 | - USD | -100.0% |
| 2003 | 2.17 Million USD | 62.91% |
| 2002 | 1.33 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 2.3 Million USD | 4.82% |
| 2024 Q1 | 2.44 Million USD | 21.53% |
| 2024 Q2 | 2.19 Million USD | -10.07% |
| 2024 FY | 9.44 Million USD | 4.41% |
| 2024 Q4 | 2.5 Million USD | 8.51% |
| 2023 Q2 | 2.06 Million USD | -10.17% |
| 2023 Q1 | 2.3 Million USD | -27.09% |
| 2023 Q4 | 2.01 Million USD | -24.54% |
| 2023 FY | 9.04 Million USD | -8.43% |
| 2023 Q3 | 2.66 Million USD | 28.93% |
| 2022 Q2 | 2.2 Million USD | -6.45% |
| 2022 Q4 | 3.15 Million USD | 46.04% |
| 2022 FY | 9.88 Million USD | -1.28% |
| 2022 Q1 | 2.35 Million USD | -10.04% |
| 2022 Q3 | 2.16 Million USD | -2.0% |
| 2021 Q2 | 2.33 Million USD | -18.0% |
| 2021 FY | 10 Million USD | -33.3% |
| 2021 Q1 | 2.84 Million USD | -33.39% |
| 2021 Q4 | 2.62 Million USD | 22.83% |
| 2021 Q3 | 2.13 Million USD | -8.57% |
| 2020 Q2 | 3.49 Million USD | -14.67% |
| 2020 FY | 15 Million USD | -25.49% |
| 2020 Q3 | 3.14 Million USD | -10.18% |
| 2020 Q4 | 4.27 Million USD | 36.02% |
| 2020 Q1 | 4.09 Million USD | -10.53% |
| 2019 Q2 | 5.07 Million USD | -3.86% |
| 2019 Q3 | 5.19 Million USD | 2.32% |
| 2019 Q1 | 5.28 Million USD | -13.12% |
| 2019 Q4 | 4.57 Million USD | -11.89% |
| 2019 FY | 20.13 Million USD | -6.33% |
| 2018 Q3 | 5.56 Million USD | 18.34% |
| 2018 FY | 21.49 Million USD | 15.33% |
| 2018 Q4 | 6.08 Million USD | 9.21% |
| 2018 Q2 | 4.7 Million USD | -8.55% |
| 2018 Q1 | 5.14 Million USD | 5.89% |
| 2017 Q3 | 5.27 Million USD | 31.05% |
| 2017 Q4 | 4.85 Million USD | -7.82% |
| 2017 Q1 | 4.49 Million USD | -2.09% |
| 2017 FY | 18.64 Million USD | 7.37% |
| 2017 Q2 | 4.02 Million USD | -10.42% |
| 2016 Q3 | 4.64 Million USD | 17.63% |
| 2016 FY | 17.36 Million USD | 24.49% |
| 2016 Q2 | 3.94 Million USD | -5.64% |
| 2016 Q1 | 4.18 Million USD | 14.76% |
| 2016 Q4 | 4.58 Million USD | -1.25% |
| 2015 Q4 | 3.64 Million USD | 1.14% |
| 2015 Q3 | 3.6 Million USD | 10.04% |
| 2015 Q2 | 3.27 Million USD | -4.21% |
| 2015 Q1 | 3.42 Million USD | -2.03% |
| 2015 FY | 13.94 Million USD | -3.47% |
| 2014 Q3 | 3.65 Million USD | -8.07% |
| 2014 Q4 | 3.49 Million USD | -4.49% |
| 2014 FY | 14.44 Million USD | 2.34% |
| 2014 Q2 | 3.97 Million USD | 19.54% |
| 2014 Q1 | 3.32 Million USD | -6.83% |
| 2013 Q2 | 4.01 Million USD | 18.88% |
| 2013 FY | 14.11 Million USD | -7.01% |
| 2013 Q3 | 3.15 Million USD | -21.56% |
| 2013 Q1 | 3.37 Million USD | -6.14% |
| 2013 Q4 | 3.57 Million USD | 13.3% |
| 2012 Q1 | 3.96 Million USD | 19.63% |
| 2012 Q3 | 4.2 Million USD | 23.42% |
| 2012 FY | 15.18 Million USD | 11.25% |
| 2012 Q4 | 3.6 Million USD | -14.41% |
| 2012 Q2 | 3.4 Million USD | -14.09% |
| 2011 Q2 | 3.31 Million USD | -12.34% |
| 2011 Q3 | 3.22 Million USD | -2.74% |
| 2011 Q4 | 3.31 Million USD | 2.76% |
| 2011 FY | 13.64 Million USD | 14.73% |
| 2011 Q1 | 3.78 Million USD | 38.95% |
| 2010 Q3 | 2.69 Million USD | -12.13% |
| 2010 Q2 | 3.06 Million USD | -9.92% |
| 2010 FY | 11.89 Million USD | -40.85% |
| 2010 Q1 | 3.4 Million USD | 14.37% |
| 2010 Q4 | 2.72 Million USD | 1.04% |
| 2009 Q4 | 2.97 Million USD | -22.71% |
| 2009 Q3 | 3.85 Million USD | -48.02% |
| 2009 Q2 | 7.41 Million USD | 31.21% |
| 2009 Q1 | 5.64 Million USD | -5.83% |
| 2009 FY | 20.1 Million USD | -14.46% |
| 2008 FY | 23.5 Million USD | 11.8% |
| 2008 Q2 | 5.96 Million USD | 5.31% |
| 2008 Q1 | 5.66 Million USD | -8.01% |
| 2008 Q3 | 5.87 Million USD | -1.46% |
| 2008 Q4 | 5.99 Million USD | 2.04% |
| 2007 Q3 | 5.4 Million USD | 14.36% |
| 2007 Q1 | 5 Million USD | 121.34% |
| 2007 Q4 | 6.15 Million USD | 13.85% |
| 2007 FY | 21.02 Million USD | 13.46% |
| 2007 Q2 | 4.73 Million USD | -5.4% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | -23.43 Million USD | 0.0% |
| 2006 FY | 18.53 Million USD | 31.01% |
| 2006 Q1 | - USD | 100.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 FY | 14.14 Million USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q4 | -17.66 Million USD | 0.0% |
| 2004 FY | - USD | -100.0% |
| 2003 FY | 2.17 Million USD | 62.91% |
| 2002 FY | 1.33 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -14.457% |
| Alpha Teknova, Inc. | 45.85 Million USD | 79.402% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | 95.18% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | 78.941% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | 94.067% |
| Cosmos Health Inc. | 26.18 Million USD | 63.92% |
| Journey Medical Corporation | 54.59 Million USD | 82.698% |
| Embecta Corp. | 528.4 Million USD | 98.212% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | 96.526% |
| Dynavax Technologies Corporation | 219.14 Million USD | 95.69% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 98.399% |
| Pacira BioSciences, Inc. | 326.37 Million USD | 97.106% |
| PainReform Ltd. | 9.58 Million USD | 1.44% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 28.028% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | 28.028% |
| SCYNEXIS, Inc. | 51.84 Million USD | 81.781% |
| Safety Shot Inc | 12.1 Million USD | 21.996% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -207.769% |
| Procaps Group, S.A. | 199.47 Million USD | 95.265% |
| Theratechnologies Inc. | 72.75 Million USD | 87.017% |
| Harrow Health, Inc. | 89.97 Million USD | 89.501% |
| Biofrontera Inc. | 39.95 Million USD | 76.361% |
| DURECT Corporation | 43.71 Million USD | 78.392% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 98.214% |
| Cronos Group Inc. | 96.7 Million USD | 90.233% |
| OptiNose, Inc. | 85.1 Million USD | 88.9% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 95.931% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | 75.874% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 198.797% |
| Organogenesis Holdings Inc. | 314.13 Million USD | 96.993% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | 2.927% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 78.053% |
| Radius Health, Inc. | 265.92 Million USD | 96.448% |
| Universe Pharmaceuticals INC | 13.84 Million USD | 31.758% |
| ProPhase Labs, Inc. | 37.85 Million USD | 75.045% |
| Phibro Animal Health Corporation | 260.29 Million USD | 96.371% |
| Procaps Group S.A. | 187.24 Million USD | 94.955% |
| Alvotech | 285.43 Million USD | 96.691% |
| TherapeuticsMD, Inc. | 9.82 Million USD | 3.858% |
| Viatris Inc. | 5.96 Billion USD | 99.842% |
| Rockwell Medical, Inc. | 15.37 Million USD | 38.559% |
| Aytu BioPharma, Inc. | 59.84 Million USD | 84.215% |
| SIGA Technologies, Inc. | 22.04 Million USD | 57.147% |
| Tilray Brands, Inc. | 251.35 Million USD | 96.242% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | 80.737% |
| Shineco, Inc. | 17.94 Million USD | 47.37% |
| PetIQ, Inc. | 192.72 Million USD | 95.099% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -136.674% |
| Incannex Healthcare Limited | 30.05 Million USD | 68.569% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.408% |
| Alimera Sciences, Inc. | 62.64 Million USD | 84.92% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -1138.833% |
| Assertio Holdings, Inc. | 368.58 Million USD | 97.437% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -60.494% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | 46.958% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | 55.378% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 55.109% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | 94.274% |
| Hempacco Co., Inc. | 7.59 Million USD | -24.348% |
| Talphera, Inc. | 11.99 Million USD | 21.244% |
| Alvotech | 285.43 Million USD | 96.691% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 93.287% |
| Lantheus Holdings, Inc. | 344.9 Million USD | 97.261% |
| Currenc Group, Inc. | 24 Million USD | 60.645% |
| Kamada Ltd. | 45.42 Million USD | 79.206% |
| Indivior PLC | 911 Million USD | 98.963% |
| Evoke Pharma, Inc. | 12.4 Million USD | 23.882% |
| Flora Growth Corp. | 10.57 Million USD | 10.71% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | 55.109% |
| Evolus, Inc. | 189.75 Million USD | 95.022% |
| HUTCHMED (China) Limited | 436.23 Million USD | 97.835% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 93.872% |
| Akanda Corp. | 3.48 Million USD | -171.163% |